Abiraterone is an oral inhibitor of cytochrome P450 (17alpha)-hydroxylase/17,20 lyase (CYP17) complex critical to androgen production. Abiraterone in combination with prednisone is currently FDA approved for use in men with metastatic castration-resistant prostate cancer, both in the pre- and post-chemotherapy settings. This article discusses the treatment with abiraterone in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
AgarwalNHutsonTEVogelzangNJ, et al.Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol2010; 6: 665–679.
2.
de BonoJSLogothetisCJMolinaA, et al.COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med2011; 364: 1995–2005.
3.
RyanCJSmithMRde BonoJS, et al.COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med2013; 368: 138–148.
4.
ZhouZRZhuXDXiaJ, et al.Short-term versus long-term hormone therapy plus radiotherapy or prostatectomy for prostate cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol2013; 139: 783–796.
5.
SharifiNGulleyJLDahutWL. Androgen deprivation therapy for prostate cancer. JAMA2005; 294: 238–244.
6.
ScherHIHellerG. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology2000; 55: 323–327.
7.
TaylorCDElsonPTrumpDL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J Clin Oncol1993; 11: 2167–2172.
8.
HakkiTBernhardtR. CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacol Ther2006; 111: 27–52.
9.
MontgomeryRBMostaghelEAVessellaR, et al.Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res2008; 68: 4447–4454.
10.
AttardGReidAHA'HernR, et al.Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol2009; 27: 3742–3748.
11.
RathkopfDESmithMRde BonoJS, et al.Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol2014; 66: 815–825.
12.
RyanCJSmithMRFizaziK, et al.COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol2015; 16: 152–160.
13.
ZhouZRLiuSXZhangTS, et al.Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev2014; 15: 1313–1320.
14.
BaschEAutioKRyanCJ, et al.Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol2013; 14: 1193–1199.
15.
RyanCJSmithMRde BonoJS, et al.COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med2013; 368: 138–148.
16.
MarburyTLawitzEStonerockR, et al.Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. J Clin Pharmacol2014; 54: 732–741.
17.
FranciniEPetrioliRFiaschiAI, et al.Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer. Medicine2014; 93: e163–e163.
